Home Tags Biofourmis

Tag: Biofourmis

Biofourmis raises 100 million dollars

Biofourmis Raises $100 Million In Series C Funding To Accelerate Global Expansion

Biofourmis, which combines AI-based data analytics and biosensors to monitor the progress of medical treatments, has raised $100 million Series C financing round led by SoftBank Vision Fund 2, with […]
Chugai Biofourmis partnership

Chugai and Biofourmis Collaborating to Develop Digital Solution For Objective Assessment of Pain

Chugai Pharmaceutical, one of Japan’s leading research-based pharmaceutical companies and Biofourmis, a Boston-based digital therapeutics company, announced that they have partnered to develop a digital solution for the objective assessment […]
Biofourmis Biovitals Sentinnel for COVID 19 patients

Biofourmis’ AI-Powered Tech Being Used in Remote Monitoring of COVID-19 Patients in Hong Kong

Biofourmis, a developer of digital therapeutics that powers personalized predictive care, announced that its technology is being leveraged in a remote monitoring and disease surveillance program in Hong Kong involving […]
Biofourmis ImagineMIC Partnership

Biofourmis Collaborates with ImagineMIC to Improve Remote Patient Monitoring for Chronic Disease Patients

Biofourmis, a fast-growing global health IT start-up founded in Singapore, and ImagineMIC, a New York-based medical device company formed a partnership to drive improved outcomes and lower healthcare costs for […]
Biofourmis buys Biovotion

Biofourmis Buys Biovotion to Deliver Precise Interventions for Patients with Complex Chronic Conditions

US-based digital therapeutics company Biofourmis has signed an agreement to buy Zurich, Switzerland-based wearable biosensor company Biovotion. The deal consists of all Biovotion’s assets, including the clinical-grade Everion® device and […]
Biofourmis CERSI study

Biofourmis to Partner with Yale University-Mayo Clinic Collaborative Program CERSI

Biofourmis, a global leader in digital therapeutics, has entered a research partnership with Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). The study, which involves patients […]